The IceCube Data Acquisition System: Signal Capture, Digitization, and Timestamping

IceCube is a km-scale neutrino observatory under construction at the South Pole with sensors both in the deep ice (InIce) and on the surface (IceTop). The sensors, called Digital Optical Modules (DOMs), detect, digitize and timestamp the signals from optical Cherenkov-radiation photons. The DOM Main Board (MB) data acquisition subsystem is connected to the central DAQ in the IceCube Laboratory (ICL) by a single twisted copper wire-pair and transmits packetized data on demand. Time calibration is maintained throughout the array by regular transmission to the DOMs of precisely timed analog signals, synchronized to a central GPS-disciplined clock. The design goals and consequent features, functional capabilities, and initial performance of the DOM MB, and the operation of a combined array of DOMs as a system, are described here. Experience with the first InIce strings and the IceTop stations indicates that the system design and performance goals have been achieved.Comment: 42 pages, 20 figures, submitted to Nuclear Instruments and Methods

Предварительное исследование применения системы спектрального регулирования для ТВС реактора ВВЭР-1000

Повышение топливных характеристик ядерных реакторов за счет применения концепции управления спектральным сдвигом (SSC) вместо традиционных методов, основанных на поглощении, является многообещающим подходом к снижению стоимости топливного цикла и увеличению использования топливных ресурсов (U, Pu). В данной работе было проведено исследование применения химического метода SSC для модели топливной сборки ВВЭР-1000 с низкообогащенным ураном, в которой контроль реактивности осуществляется путем изменения доли D2O относительно легководного замедлителя (D2O/H2O), и сравнение с поглощающими материалами, в которых содержится 600 ppm H3BO3 и 4,0 мас.% Gd2O3

Computer Simulation of Automobile Fires

Using CFD (Computer Fluid Dynamics) theory and its practical knowledge has become widespread in such academic disciplines as aerodynamics, fluid dynamics, combustion engineering and other fields. However, in disciplines, which examine the ongoing processes in larger sizes, CFD was applied during the last decade only. One of such discipline is a spread of fire. Fire processes are a very complicated and complex phenomenon consisting of combustion, radiation, turbulence, fluid dynamics, pressure and other physical and chemical processes. In the paper, we describe the use of FDS (Fire Dynamics Simulator) for the simulation of automobile/vehicle fires in different environment

Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies

Background: Rivaroxaban has been shown to be efficacious for treatment of venous thromboembolism in adults, and has a reduced risk of bleeding compared with standard anticoagulants. We aimed to develop paediatric rivaroxaban regimens for the treatment of venous thromboembolism in children and adolescents. Methods: In this phase 2 programme, we did three studies to evaluate rivaroxaban treatment in children younger than 6 months, aged 6 months to 5 years, and aged 6–17 years. Our studies used a multicentre, single-arm design at 54 sites in Australia, Europe, Israel, Japan, and north America. We included children with objectively confirmed venous thromboembolism previously treated with low-molecular weight heparin, fondaparinux, or a vitamin K antagonist for at least 2 months or, in children who had catheter-related venous thromboembolism for at least 6 weeks. We administered rivaroxaban orally in a bodyweight-adjusted 20 mg-equivalent dose, based on physiologically-based pharmacokinetic modelling predictions and EINSTEIN-Jr phase 1 data in young adults, in either a once-daily (tablets; for those aged 6–17 years), twice-daily (in suspension; for those aged 6 months to 11 years), or three times-daily (in suspension; for those younger than 6 months) dosing regimen for 30 days (or 7 days for those younger than 6 months). The primary aim was to define rivaroxaban treatment regimens that match the target adult exposure range. The principal safety outcome was major bleeding and clinically relevant non-major bleeding. Analyses were per-protocol. The predefined efficacy outcomes were symptomatic recurrent venous thromboembolism, asymptomatic deterioration on repeat imaging at the end of the study treatment period. These trials are registered at ClinicalTrials.gov, numbers NCT02564718, NCT02309411, and NCT02234843. Findings: Between Feb 11, 2013, and Dec 20, 2017, we enrolled 93 children (ten children younger than 6 months; 15 children aged 6 months to 1 year; 25 children aged 2–5 years; 32 children aged 6–11 years; and 11 children aged 12–17 years) into our study. 89 (96%) children completed study treatment (30 days of treatment, or 7 days in those younger than 6 months), and 93 (100%) children received at least one dose of study treatment and were evaluable for the primary endpoints. None of the children had a major bleed, and four (4%, 95% CI 1·2–10·6) of these children had a clinically relevant non-major bleed (three children aged 12–17 years with menorrhagia and one child aged 6–11 years with gingival bleeding). We found no symptomatic recurrent venous thromboembolism in any patients (0%, 0·0–3·9). 24 (32%) of 75 patients with repeat imaging had their thrombotic burden resolved, 43 (57%) patients improved, and eight (11%) patients were unchanged. No patient deteriorated. We confirmed therapeutic rivaroxaban exposures with once-daily dosing in children with bodyweights of at least 30 kg and with twice-daily dosing in children with bodyweights of at least 20 kg and less than 30 kg. Children with low bodyweights (<20 kg, particularly <12 kg) showed low exposures so, for future studies, rivaroxaban dosages were revised for these weight categories, to match the target adult exposure range. 61 (66%) of 93 children had adverse events during the study. Pyrexia was the most common adverse event (ten [11%] events), and anaemia and neutropenia or febrile neutropenia were the most frequent grade 3 or worse events (four [4%] events each). No children died or were discontinued from rivaroxaban because of adverse events. Interpretation: Treatment with bodyweight-adjusted rivaroxaban appears to be safe in children. The treatment regimens that we confirmed in children with bodyweights of at least 20 kg and the revised treatment regimens that we predicted in those with bodyweights less than 20 kg will be evaluated in the EINSTEIN-Jr phase 3 trial in children with acute venous thromboembolism. Funding: Bayer AG, Janssen Research and Development

Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies

Rivaroxaban has been shown to be efficacious for treatment of venous thromboembolism in adults, and has a reduced risk of bleeding compared with standard anticoagulants. We aimed to develop paediatric rivaroxaban regimens for the treatment of venous thromboembolism in children and adolescents

Results from the AMANDA neutrino telescope

We review recent results from AMANDA on the search for cosmic point sources of neutrinos, both in the diffuse and point-like channels. Assuming a E-2 spectral shape of the neutrino energy at the source, we derive limits on the diffuse \u3bd\u3bc flux as well as in the all-flavour diffuse flux from the cascade search. We report limits on selected point sources as well as on GRB searches. We present results on primary cosmic CR composition in the range 3c100 TeV-PeV obtained with the help of the SPASE air shower array run in coincidence with AMANDA. \ua9 2004 Elsevier B.V. All rights reserved

Flux limits on ultra high energy neutrinos with AMANDA-B10

Data taken during 1997 with the AMANDA-B10 detector are searched for a diffuse flux of neutrinos of all flavors with energies above 1016eV. At these energies the Earth is opaque to neutrinos, and thus neutrino induced events are concentrated at the horizon. The background are large muon bundles from down-going atmospheric air shower events. No excess events above the background expectation are observed and a neutrino flux following E-2, with an equal mix of all flavors, is limited to E2φ(1015eV < E < 3 × 1018eV) ≤ 0.99 × 10-6GeV cm-2 s-1 sr-1 at 90% confidence level. This is the most restrictive experimental bound placed by any neutrino detector at these energies. Bounds to specific extra-terrestrial eutrino flux predictions are also presented. © 2004 Elsevier B.V. All rights reserved.0SCOPUS: ar.jinfo:eu-repo/semantics/publishe